Our Faculty

Tomasz M. Beer, M.D.
Grover C. Bagby Endowed Chair for Prostate Cancer Research
Section Head, Solid Tumor Oncology
Associate Professor of Medicine

Specialty: Medical Oncology, Prostate Cancer

Clinic Phone: 503-494-6594
E-mail: beert@ohsu.edu

Tomasz M. Beer, M.D. is Associate Professor of Medicine, Division of Hematology & Medical Oncology at Oregon Health & Science University in Portland, Oregon. He received his medical degree from Johns Hopkins School of Medicine, Baltimore, Maryland, in 1991. He then moved to Oregon Health Sciences University. At OHSU he completed his internship and residency in internal medicine and then completed his fellowship in Hematology and Medical Oncology. Currently, he is a member of several professional societies, including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, and Southwest Oncology Group. He has also authored and co-authored more than 150 articles and abstracts on prostate cancer, and is actively investigating calcitriol for prostate cancer prevention and treatment, as well as treatments for androgen-independent prostate cancer. Dr. Beer's major research interests include clinical trials, preclinical investigation, and risk factors in prostate cancer.  

• Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A. Statins and prostate cancer risk: a case-control study, American Journal of Epidemiology, 162(4):318-25, 2005.
  
• Bussiere JR, Beer TM, Neiss MB, and Janowsky JS. Androgen Deprivation Impairs Memory in Older Men, Behavioral Neuroscience, 119(6):1429-37, 2005. 
  
• Beer TM and Myrthue A. Calcitriol in the Treatment of Prostate Cancer. Anticancer Research, 25(4A):2647-2651, 2006. 
  
• Lycette JL, Bland LB, Garzotto M, and Beer TM. The Case for Parenteral Estrogens for Prostate Cancer. Clinical GU Cancer, 5:198-205, 2006. 
  
• Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Curd JG, Arroyo A, Clow FW. High dose calcitriol may reduce thrombosis in cancer patients. British Journal of Hematology, 135(3):392-4, 2006. 
  
• Beer TM, Javle M, Ryan CW, Wong A, Lam GN, Henner WD, and Trump DL. Phase I study of Weekly DN-101, a New Formulation of Calcitriol, in Patients with Cancer. Cancer Chemotherapy and Pharmacology, 2006 Oct 26 
  
• True L, Coleman I, Hawley S, Huang A, Gifford D, Coleman R, Beer TM, Vessella R, Lin D, Hood L, and Nelson PS. A Molecular Correlate to the Gleason Grading System for Prostate Adenocarcinoma, Proc Natl Acad Sci U S A. 103(29):10991-6, 2006. 
  
• Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, Deloughery TG, Crawford ED. Prognostic Value of Hemoglobin Change After Initiation of Androgen Deprivations Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis Of SWOG 8894. Cancer, 107:489-96, 2006. 
  
• Beer TM, Bland LB, Bussiere JR, Neiss M, Wersinger EM, Garzotto M, Ryan CW, and Janowsky JS. Testosterone loss and estradiol administration modifies memory in men, Journal of Urology, 175(1):130-5, 2006. 
  
• Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, and Beer TM. Effect of transdermal estrogen therapy levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. Journal of Lipid Research, 47(2):349-55, 2006.
  
• Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario V, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW. ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Journal of Clinical Oncology, February 20, 2007.

Search PubMed for more publications